Wei Xu
Directeur/Membre du Conseil chez UGenix Biotech Ltd.
Profil
Wei Xu has held positions as a Director at AnHeart Therapeutics, Inc., a Non-Executive Director at UGenix Biotech Ltd., and a Partner at Decheng Capital LLC.
Postes actifs de Wei Xu
| Sociétés | Poste | Début |
|---|---|---|
Decheng Capital LLC
 Decheng Capital LLC Investment ManagersFinance Decheng Capital LLC is a venture capital firm founded by Min Cui in 2011 having headquartered at Shanghai, China. | Private Equity Investor | 01/01/2017 |
AnHeart Therapeutics, Inc.
 AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | Directeur/Membre du Conseil | - |
UGenix Biotech Ltd.
 UGenix Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services UGenix Biotech Ltd. is a holding company, which engages in the provision of prenatal testing, precision oncology, and pathogenic detection services. The company was founded on October 26, 2021 and is headquartered in Hong Kong. | Directeur/Membre du Conseil | 01/04/2022 |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Entreprise privées | 3 |
|---|---|
Decheng Capital LLC
Decheng Capital LLC Investment ManagersFinance Decheng Capital LLC is a venture capital firm founded by Min Cui in 2011 having headquartered at Shanghai, China. | Finance |
AnHeart Therapeutics, Inc.
AnHeart Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Part of Nuvation Bio, Inc., AnHeart Therapeutics, Inc. is a clinical stage biopharmaceutical company based in New York, NY. AnHeart Therapeutics is focused on developing a pipeline of novel precision oncology therapeutics for areas of significant unmet medical need. The company's lead investigational therapy, taletrectinib, is a next-generation ROS1-inhibitor currently in pivotal phase 2 trials for ROS1-positive non-small cell lung cancer (NSCLC). AnHeart Therapeutics, Inc. also has a second investigational therapy, safusidenib, being evaluated in a phase 2 trial for -mutant glioma. AnHeart Therapeutics is supported by leading life sciences investors and has built an organization with deep oncology drug discovery and development expertise. The company was founded by Bing Yan, Junyuan Jerry Wang, Lihua Zheng, and the CEO is Junyuan Jerry Wang. AnHeart Therapeutics was acquired by Nuvation Bio, Inc. on April 09, 2024 for $89.30 million. | Health Technology |
UGenix Biotech Ltd.
UGenix Biotech Ltd. Miscellaneous Commercial ServicesCommercial Services UGenix Biotech Ltd. is a holding company, which engages in the provision of prenatal testing, precision oncology, and pathogenic detection services. The company was founded on October 26, 2021 and is headquartered in Hong Kong. | Commercial Services |
